PMID- 30861411
OWN - NLM
STAT- MEDLINE
DCOM- 20190806
LR  - 20190806
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 113
DP  - 2019 May
TI  - Mechanistic evaluation of anti-arthritic activity of beta-methylphenylalanine in 
      experimental rats.
PG  - 108730
LID - S0753-3322(19)30559-1 [pii]
LID - 10.1016/j.biopha.2019.108730 [doi]
AB  - Arthritis is a common chronic joint disorder, with general symptoms including 
      stiffness and joint pain. beta-methylphenylalanine is a well-known non-proteogenic 
      unnatural amino acid. This study analyzes the anti-arthritic activity of 
      beta-methylphenylalanine in experimental rats. The experimental groups were as 
      follows: group I, sham; group II, control; group III, 100 mg/kg of 
      beta-methylphenylalanine; and group IV, 200 mg/kg of beta-methylphenylalanine. Lipid 
      peroxidation, glutathione peroxidase (Gpx), reduced glutathione (GSH), superoxide 
      dismutase (SOD), catalase, prostaglandin E(2) (PGE(2)), matrix 
      metalloproteinase-3 (MMP-3), ceruloplasmin, zinc, copper, mRNA, and protein 
      expression of inducible nitric oxide synthase (iNOS) and nuclear factor-kappa B 
      (NF-kappaB) were determined. Supplementation with beta-methylphenylalanine significantly 
      reduced lipid peroxidation, copper, PGE(2) and MMP-3 levels, whereas GSH, Gpx, 
      catalase, SOD and zinc levels were increased. Supplementation with 
      beta-methylphenylalanine significantly reduced NF-kappaB mRNA expression by 26% and 
      47.8% in groups III and IV, respectively (P < 0.045), while iNOS mRNA expression 
      was reduced by 14.3 and 47.6% in groups III and IV, respectively. NF-kappaB and iNOS 
      protein expression increased by 160% and 120% respectively, in the control rats 
      compared to the sham rats. However, supplementation with beta-methylphenylalanine 
      significantly reduced NF-kappaB protein expression by 27% and 50% in groups III and 
      IV, respectively, while iNOS protein expression was reduced by 22.7% and 45.4% in 
      groups III and IV, respectively. Taken together, our data show that 
      supplementation of beta-methylphenylalanine was effective against arthritis in a rat 
      model.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Ren, Shi-Xiang
AU  - Ren SX
AD  - Department of Orthopedics, Beijing Chaoyang Hospital Affiliated to Capital 
      Medical University, Beijing, 100020, China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Department of Orthopedics, Beijing Chaoyang Hospital Affiliated to Capital 
      Medical University, Beijing, 100020, China.
FAU - Lin, Yuan
AU  - Lin Y
AD  - Department of Orthopedics, Beijing Chaoyang Hospital Affiliated to Capital 
      Medical University, Beijing, 100020, China.
FAU - Ma, De-Si
AU  - Ma DS
AD  - Department of Orthopedics, Beijing Chaoyang Hospital Affiliated to Capital 
      Medical University, Beijing, 100020, China.
FAU - Li, Huan
AU  - Li H
AD  - Department of Orthopedics, The First People's Hospital of Changzhou, Jiangsu 
      Province (The Third Affiliated Hospital of Soochow University), Changzhou City, 
      Jiangsu Province, 213003 China. Electronic address: aomoign@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20190309
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Aminobutyrates)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (NF-kappa B)
RN  - 0 (RNA, Messenger)
RN  - 2260-12-0 (2-amino-3-phenylbutanoic acid)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - GAN16C9B8O (Glutathione)
RN  - J41CSQ7QDS (Zinc)
RN  - K7Q1JQR04M (Dinoprostone)
MH  - Aminobutyrates/administration & dosage/*pharmacology
MH  - Animals
MH  - Antirheumatic Agents/administration & dosage/*pharmacology
MH  - Arthritis, Experimental/*drug therapy/pathology
MH  - Catalase/metabolism
MH  - Dinoprostone/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Glutathione/metabolism
MH  - Glutathione Peroxidase/metabolism
MH  - Lipid Peroxidation/*drug effects
MH  - Male
MH  - NF-kappa B/metabolism
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Superoxide Dismutase/metabolism
MH  - Zinc/metabolism
OTO - NOTNLM
OT  - Arthritis
OT  - Lipid peroxidation
OT  - Rats
OT  - mRNA
OT  - beta-methylphenylalanine
EDAT- 2019/03/13 06:00
MHDA- 2019/08/07 06:00
CRDT- 2019/03/13 06:00
PHST- 2019/02/05 00:00 [received]
PHST- 2019/02/20 00:00 [revised]
PHST- 2019/02/22 00:00 [accepted]
PHST- 2019/03/13 06:00 [pubmed]
PHST- 2019/08/07 06:00 [medline]
PHST- 2019/03/13 06:00 [entrez]
AID - S0753-3322(19)30559-1 [pii]
AID - 10.1016/j.biopha.2019.108730 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2019 May;113:108730. doi: 10.1016/j.biopha.2019.108730. Epub 
      2019 Mar 9.